Login to Your Account

A Return Home

Win! Win! Biogen Pays Up for Outsourcing, Avoids Risk

By Brian Orelli
BioWorld Insight Contributing Writer

Tuesday, February 21, 2012

Last week, Biogen Idec Inc. announced the purchase of Stromedix Inc. to gain access to the start-up's humanized monoclonal antibody, STX-100. The purchase marks a return home for the integrin avb6-targeted drug, which was originally developed by Biogen. (See BioWorld Today, Feb. 15, 2012.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription